The following article is for satirical and entertainment purposes only. Any attempts at litigation will be shamelessly capitalized upon to create a media circus and further amplify the author's personal brand.
BOSTON — In a development that has sent shockwaves through the psychedelic pharmaceutical industry, the Institute for Clinical and Economic Review (ICER) has reportedly recommended that Compass Pathways slash the cost of its proprietary psilocybin treatment, COMP360, by 99%. The review effectively recommends that Compass go touch grass—or visit a smoke shop, a college dorm, or literally anywhere with wood chips and a humid climate, where a better version of its product that is projected to cost up to $65,000 is readily available either for free or about $20.
The recommendation threatens to undermine years of painstaking work by psychedelic executives to convince investors that naturally occurring fungal compounds become exponentially more valuable when wrapped in intellectual property, administered in a carefully curated clinical setting, and accompanied by a PowerPoint presentation explaining why traditional mushroom use doesn't count as medicine.
“It's a devastating blow to innovation,” said Kevin Ballsach of Psychedelic Industry astroturfing outfit Psychedelic Beta while staring blankly at a spreadsheet projecting $14 billion in annual revenue from people who are sad. “If we can't charge exploitative pharmaceutical prices for a cheap simulacrum of mushrooms, what's stopping people from growing them in their basements and experiencing the therapeutic benefits known and loved by tens of millions of people already without generating shareholder value?”
Compass Pathways has spent years developing COMP360, its proprietary synthetic psilocybin formulation, as a potential treatment for mental health conditions. The company's broader ambitions reflect a growing effort to integrate psychedelic-assisted therapy into mainstream healthcare, where clinical evidence, regulatory approval, and reimbursement negotiations determine whether promising treatments can reach patients.
Unfortunately, ICER's reported recommendation threatens to introduce an unwelcome variable into the equation: affordability.
“Our last ditch Hail Mary for this to work is called Bifurcated Scheduling; it’s where our proprietary psilocybin asset is bumped down to Schedule lll and treated like some kind of miracle breakthrough cure, while mushrooms that grow in the ground and have been used for millennia in a pan-global tradition and that cost about $100 to grow a lifetime supply of remain Schedule l and have potentially severe criminal statues applied to anyone who dares consume them,” said a company representative.
Industry observers fear that if psychedelic medicines become too inexpensive, pharmaceutical companies could lose the financial incentive to discover that ancient healing practices have measurable therapeutic benefits.
Meanwhile, underground mushroom enthusiasts expressed confusion over the controversy.
“Wait, you're telling me the drug is basically psilocybin?” asked one home cultivator, who declined to identify himself due to high profit margins from trapping. “And you want people to pay how much?”
At press time, Compass Pathways was reportedly exploring a new contract with The Pentagon to see if they could swing a deal with DynCorp to get COMP360 approved for use in the defense industry, where price gouging can be more readily concealed under the auspices of national security.
The future of psychedelic medicine has never looked more promising, thanks to the Trojan Horse for crowd-sourced mushroom access that medicalization and primetime coverage from companies like Compass has afforded.